IDH2 and central nervous system cancer: Interestingly, we also show that PDL1/2 promoter hypomethylation and expression are strongly associated with a glycolytic-high phenotype, layering a potential epigenetic immunosuppressive explanation for the poorer prognosis of IDH-wt glioma patients.